Video

Dr. Gasparetto on Efficacy of Selinexor Combination in Multiple Myeloma

Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discuss the efficacy of selinexor in combination with dexamethasone for the treatment of patients with multiple myeloma.

Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discuss the efficacy of selinexor in combination with dexamethasone and daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

This combination is not approved by the FDA but researchers are still accumulating data, explains Gasparetto. Both are being investigated in phase III trials, creating potential for 2 additional drugs for the treatment of patients with multiple myeloma.

The number of patients treated on the combination study was very small, but Gasparetto says that the community is excited about the signal the treatment is showing. Selinexor was previously investigated in combination with dexamethasone in refractory patients with multiple myeloma, where it showed efficacy as a single-agent.

In this trial, selinexor combined with weekly bortezomib (Velcade) and low-dose dexamethasone produced rapid and durable responses in a dose escalation/expansion trial of patients with relapsed/refractory multiple myeloma. The overall response rate was 84% in patients who had relapsed after a proteasome inhibitor (PI) or were naïve to a PI, and 43% in patients whose disease was refractory to a PI.

Related Videos
Shella Saint Fleur-Lominy, MD, PhD
Benjamin Levy, MD
Nader Sanai, MD, chief, Neurosurgical Oncology, director, Ivy Brain Tumor Center, Barrow Neurological Institute
Manali Kamdar, MD
Ibrahim Aldoss, MD
Barbara Burtness, MD
Natalia Neparidze, MD
Arya Mariam Roy, MBBS
Pamela L. Kunz, MD, associate professor, internal medicine (medical oncology), Yale School of Medicine; director, Center for Gastrointestinal (GI) Cancers, chief, GI Medical Oncology, Smilow Cancer Hospital, Yale Cancer Center
Matthew Matasar, MD, chief, Division of Blood Disorders, Rutgers Cancer Institute; professor, medicine, Rutgers Robert Wood Johnson Medical School